ITGB3 and osteosarcoma: These results were consistent with the report by Meloche.9 MiR‐223‐3p was reported to have an anti‐tumour role in head and neck squamous cell carcinoma and osteosarcoma and suppresses angiogenesis or cell metastasis via targeting cadherin‐6 (CDH6) and other targets.42, 43 In this study, we proposed that miR‐223‐3p targets ITGB3 to participate in the process of PAH.